1644-71-9

Basic information

• Product Name: 5-BROMO-4-FLUOROSALICYLIC ACID
• Synonyms: 5-BROMO-4-FLUOROSALICYLIC ACID;5-BroMo-4-fluoro-2-hydroxybenzoic acid;5-Bromo-4-fluoro-2-hydroxybenzoic acid 96%;5-Bromo-4-fluorosalicylic acid, 4-Bromo-2-carboxy-5-fluorophenol;5-Bromo-4-fluoro-2-hydroxybenzoicacid96%
• CAS NO: 1644-71-9
• Molecular Formula: C₇H₄BrFO₃
• Molecular Weight: 235.01
• Mol File: 1644-71-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 208 °C(Solv: ethanol (64-17-5))
• Boiling Point: 341.4°Cat760mmHg
• Flash Point: 160.3°C
• Appearance: /
• Density: 1.945g/cm³
• Vapor Pressure: 3.1E-05mmHg at 25°C
• Refractive Index: 1.625
• PKA: 2.36±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-4-FLUOROSALICYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-4-FLUOROSALICYLIC ACID(1644-71-9)
• EPA Substance Registry System: 5-BROMO-4-FLUOROSALICYLIC ACID(1644-71-9)

Safety Data

• Hazardous Substances Data: 1644-71-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-4-fluorosalicylic acid is a chemical compound that belongs to the class of salicylic acids. It is a derivative of salicylic acid and contains a bromine and fluorine atom on the benzene ring. 5-BROMO-4-FLUOROSALICYLIC ACID is used in various applications, including as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. It is also used in the production of organic building blocks and in research and development for creating new compounds. Additionally, 5-Bromo-4-fluorosalicylic acid has potential applications in the field of materials science and as a reagent in organic chemistry reactions.

InChI:InChI=1/C7H4BrFO3/c8-4-1-3(7(11)12)6(10)2-5(4)9/h1-2,10H,(H,11,12)

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 

Downstream Products

• 4133-72-6 methyl 5-bromo-4-fluoro-2-hydroxybenzoate 
• 1262048-06-5 benzyl 2-(benzyloxy)-5-bromo-4-fluorobenzoate 
• 927391-87-5 5-bromo-4-fluoro-2-hydroxy-3-nitrobenzoic acid 
• 1026876-50-5 5-bromo-4-fluoro-2-hydroxybenzamide 

Relevant articles and documents

Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens

A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.

A convenient and efficient H2SO4-promoted regioselective monobromination of phenol derivatives using N-bromosuccinimide

A convenient, rapid H2SO4-promoted regioselective monobromination reaction with N-bromosuccinimide was developed. The desired para-monobrominated or ortho-monobrominated products of phenol derivatives were obtained in good to excellent yields with high selectivity. Regioselective chlorination and iodination were also achieved in the presence of H2SO4 using N-chlorosuccinimide and N-iodosuccinimide, respectively.

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.